Migami, Inc. Profits $1.5 Million from Peptide Sublicense

LOS ANGELES--(BUSINESS WIRE)--Migami, Inc. (OTCBB: MIGA.OB) has agreed to sublicense its rights to several peptide molecules related to alpha-melanocyte-stimulating hormones to Migami Korea, Ltd. (MKL) for $1.5 million and anticipated royalties. The sublicense agreement specifies the territory as South Korea, and the expiration of the patents will effectively terminate the contract.

This agreement marks another milestone in Migami’s continual sublicensing efforts throughout the Pacific Rim. Once Migami’s various technologies are commercialized in a specified territory, Migami generates ongoing revenues from royalties and manufacturing.

Migami looks forward to sublicensing this peptide technology in other Asian countries.

Safe Harbor Act Disclaimer

The information contained in this release, other than historical information, may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Projections and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events or results may differ materially

Migami, Inc., Los Angeles
John Park, 213/739-1700